Search
Nitroprusside
go.drugbank.com/drugs/DB00325ApprovedInvestigationalNitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing...
Midecamycin
go.drugbank.com/drugs/DB13456Investigational[A33075] Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.[L2791]
Matrix-M
go.drugbank.com/drugs/DB16369InvestigationalMatrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax.
Methscopolamine bromide
go.drugbank.com/drugs/DB00462ApprovedA muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Friulimicin B
go.drugbank.com/drugs/DB06087InvestigationalFriulimicin B is a naturally occurring antibiotic produced by a micro-organism, *Actinoplanes friuliensis*.
ALTU-135
go.drugbank.com/drugs/DB05330InvestigationalALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA). … ALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase
Acetylcysteine
go.drugbank.com/drugs/DB06151ApprovedInvestigationalAcetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results. Ac...
PRO 2000
go.drugbank.com/drugs/DB05385InvestigationalPRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.
Delamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalDelamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan).
Simoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedThe harvested product is concentrated and purified by a series of chromatography steps. … acids with an approximate molecular mass of 170 kDa, comprising the FVIII domains A1-A2 + A3-C1-C2 whereas the B-domain, present in the full-length plasma-derived FVIII, has been deleted and replaced by